1. A5.07 The role of immunologic and inflammatory factors in the risk of microvascular and macrovascular impairment development in systemic lupus erythematosus – preliminary data. (24th February 2016) Authors: Fischer, K; Sawicki, M; Chamiak-Ciemińska, K; Stolarczyk, J; Winikajtis-Burzyńska, A; Milchert, M; Ostanek, L; Bobrowska-Snarska, D; Kapłon, Ł; Przepiera-Będzak, H; Walecka, A; Brzosko, I; Brzosko, M Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 1 Page Start: A44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A6.25 Serum concentrations of vascular endothelial growth factor in systemic lupus erythematosus – association with autoantibody profile and cardiovascular involvement. (13th February 2015) Authors: Fischer, K; Przepiera-Będzak, H; Ostanek, L; Walecka, A; Sawicki, M; Brzosko, I; Brzosko, M Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0130 Relationship between presence of neurological symptoms and activity of systemic lupus erythematosus. (1st June 2001) Authors: Ostanek, L; Honczarenko, K; Fischer, K; Fiedorowicz-Fabrycy, I Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗